Lafutidine , ≥99% , 118288-08-7

CAS NO.：118288-08-7

Empirical Formula: C22H29N3O4S

Molecular Weight: 431.55

MDL number: MFCD00867520

EINECS: 601-513-8

PRODUCT Properties

• Melting point: 92.7-94.9°
• Boiling point: 704.2±60.0 °C(Predicted)
• Density: 1.252±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• Water Solubility: Insoluble in water
• solubility: DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM); DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM); DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM); Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM)
• form: powder to crystal
• pka: 13.13±0.46(Predicted)
• color: White to Orange to Green

Description and Uses

Lafutidine is a histamine H₂ receptor antagonist with gastroprotective activity. It inhibits histamine-induced cAMP production in CHO cells expressing human histamine H₂ receptors when used at a concentration of 10 nM. Intragastric administration of lafutidine (3, 10, and 30 mg/kg) reduces hemorrhagic esophageal lesion size and gastric acid secretion in a rat model of pyloric ligation-induced reflux esophagitis. It prevents 5-fluorouracil-induced intestinal mucositis, diarrhea, and body weight loss in wild-type, but not Trpv1^-/- or sensory deafferented, mice when administered at doses ranging from 3 to 30 mg/kg. Lafutidine (10 mg/kg) also reduces indomethacin-induced antral ulcer size in wild-type, but not chemically-deafferented, rats.

Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• Safety Statements: 24/25
• HS Code: 29349990